About Robert Nelsen
Robert Nelsen is a 10% owner at Boundless Bio.
Form D filings name Robert Nelsen as a director at Seaport Therapeutics.
Robert Nelsen reports to the SEC as a director or major shareholder of 48 public companies, including Kardigan (KARD), Prime Medicine (PRME) and Sana Biotechnology (SANA).
Robert Nelsen first appears on SEC filings in 2006.
Experience
This experience comes from SEC filings. The years are when the filings name Robert Nelsen in the role, so the role may have started earlier or lasted longer.
BI
KI
Kardigan, Inc.
Director and 10% owner
2026 · Public company (KARD)
PI
Prime Medicine, Inc.
Director and 10% owner
2022 – 2026 · Public company (PRME)
SI
Sana Biotechnology, Inc.
Director and 10% owner
2021 – 2026 · Public company (SANA)
LI
Lyell Immunopharma, Inc.
Director and 10% owner
2021 – 2026 · Public company (LYEL)
MI
NI
Neumora Therapeutics, Inc.
10% owner
2023 – 2025 · Public company (NMRA)
MI
Maze Therapeutics, Inc.
10% owner
2025 · Public company (MAZE)
RI
Rapport Therapeutics, Inc.
10% owner
2024 · Public company (RAPP)
VI
Vir Biotechnology, Inc.
Director and 10% owner
2019 – 2024 · Public company (VIR)
DC
DA32 Life Science Tech Acquisition Corp.
10% owner
2021 – 2023 · Public company (DALS)
CI
Codiak BioSciences, Inc.
10% owner
2020 – 2022 · Public company (CDAK)
EI
Erasca, Inc.
10% owner
2021 · Public company (ERAS)
BI
Beam Therapeutics Inc.
Director and 10% owner
2020 – 2021 · Public company (BEAM)
VI
Verve Therapeutics, Inc.
10% owner
2021 · Public company (VERV)
DI
Denali Therapeutics Inc.
Director and 10% owner
2017 – 2021 · Public company (DNLI)
KI
Karuna Therapeutics, Inc.
Director and 10% owner
2019 – 2021 · Public company (KRTX)
RC
Revolution Healthcare Acquisition Corp.
Director
2021 · Public company (REVH)
9I
908 Devices Inc.
10% owner
2020 · Public company (MASS)
QC
Quanterix Corp
10% owner
2017 – 2020 · Public company (QTRX)
MI
Metacrine, Inc.
10% owner
2020 · Public company (MTCR)
UI
Unity Biotechnology, Inc.
Director and 10% owner
2018 – 2020 · Public company (UBX)
SI
Syros Pharmaceuticals, Inc.
Director and 10% owner
2016 – 2019 · Public company (SYRS)
QI
Q32 Bio Inc.
10% owner
2018 – 2019 · Public company (QTTB)
SI
Sienna Biopharmaceuticals, Inc.
Director and 10% owner
2017 – 2019 · Public company (SNNA)
GI
Gossamer Bio, Inc.
10% owner
2019 · Public company (GOSS)
TC
Twist Bioscience Corp
10% owner
2018 · Public company (TWST)
SC
Scholar Rock Holding Corp
10% owner
2018 · Public company (SRRK)
PI
Pulmatrix, Inc.
10% owner
2015 – 2018 · Public company (PULM)
JI
Juno Therapeutics, Inc.
Director and 10% owner
2014 – 2018 · Public company (JUNO)
AI
Agios Pharmaceuticals, Inc.
Director and 10% owner
2013 – 2017 · Public company (AGIO)
XI
Xtera Communications, Inc.
10% owner
2015 – 2016 · Public company (XCOM)
II
Impinj Inc.
10% owner
2016 · Public company (PI)
PI
Phaserx, Inc.
10% owner
2016 · Public company (PZRX)
SI
Sage Therapeutics, Inc.
Director and 10% owner
2014 – 2015 · Public company (SAGE)
AC
Adesto Technologies Corp.
10% owner
2015 · Public company (IOTS)
VI
Vbi Vaccines Inc.
10% owner
2014 – 2015 · Public company (VBIV)
KI
Kythera Biopharmaceuticals Inc.
Director and 10% owner
2012 – 2015 · Public company (KYTH)
BI
Bellerophon Therapeutics, Inc.
Director and 10% owner
2015 · Public company (BLPH)
RI
Receptos, Inc.
10% owner
2013 – 2014 · Public company (RCPT)
AI
Achaogen, Inc.
10% owner
2014 · Public company (AKAO)
FI
Fate Therapeutics Inc.
Director and 10% owner
2013 · Public company (FATE)
BI
bluebird bio, Inc.
10% owner
2013 · Public company (BLUE)
NI
NeurogesX Inc
Director and 10% owner
2007 – 2012 · Public company (NGSX)
TI
Trubion Pharmaceuticals, Inc
10% owner
2006 – 2010 · Public company (TRBN)
CI
Celebrate Express, Inc.
10% owner
2008 · Public company (BDAY)
AC
Adolor Corp.
Director
2006 – 2007 · Public company (ADLR)
Key Colleagues at Startups
The people Robert Nelsen works with at each company, as listed on that company's latest Form D.
Seaport Therapeutics, Inc. · Form D, Oct 31, 2024
JH
James Healy
Director
MC
Michael Chen
Executive officer
LG
Lana Gladstein
General Counsel
DZ
Daphne Zohar
Executive officer and director
AL
Antony Loebel
Executive officer
DW
David Wheadon
Director
EG
Eric Green
Executive officer
SP
Steven Paul
Director
BC
Bharatt Chowrira
Director
DT
Denice Torres
Director
EE
Eric Elenko
Director
JP
Jason Pitts
Director